Read + Share
Al-Jabri R, Afif W. In moderately to severely active UC, etrasimod increased remission at 12 and 52
wk but increased adverse events. Ann Intern Med 2023;176:JC82.
PMID: 37399559
|
 |
|
Al-Jabri R, Afif W. In moderately to severely active UC, etrasimod increased remission at 12 and 52
wk but increased adverse events. Ann Intern Med 2023;176:JC82.
PMID: 37399559
|
|
|
|